Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jon Bragi Bergmann"'
Autor:
Anniken Bjørnstad Østensen, Erik Schrumpf, P. F. Jørgensen, Jon Hausken, Svein Osnes, Stein Foss, Truls Sanengen, Jon Bragi Bergmann, Pål-Dag Line, Rikshospitalet Levertransplantasjonsgruppen ved Oslo universitetssykehus, Fridtjov Riddervold, Aksel Foss, Kirsten Muri Boberg, Håkon Haugaa, T. Scholz, Kristian Bjøro, Tom H. Karlsen, Bjarte Fosby, O Bentdal
Publikováno v:
Tidsskrift for Den norske legeforening. 129:2587-2592
Background In Norway, liver transplantation has been the treatment of choice for irreversible acute and chronic liver failure for 25 years. The aim of this article is to present a summary of the results obtained. Material and methods All liver transp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a03b0706fc7f96c3c092637eccec6db
https://doi.org/10.4045/tidsskr.09.1106
https://doi.org/10.4045/tidsskr.09.1106
Autor:
Tim, Scholz, Tom H, Karlsen, Truls, Sanengen, Erik, Schrumpf, Pal Dag, Line, Kirsten Muri, Boberg, Pal Foyn, Jörgensen, Bjarte, Fosby, Oystein, Bentdal, Anniken Björnstad, Ostensen, Svein, Osnes, Fridtjov, Riddervold, Hakon, Haugaa, Jon, Hausken, Jon Bragi, Bergmann, Stein, Foss, Kristian, Björo, Aksel, Foss, Kristian, Bjøro
Publikováno v:
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 129(24)
In Norway, liver transplantation has been the treatment of choice for irreversible acute and chronic liver failure for 25 years. The aim of this article is to present a summary of the results obtained.All liver transplants performed in Norway in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4c5f6b48452f83d6249e74d4ce560021
https://pubmed.ncbi.nlm.nih.gov/20029553
https://pubmed.ncbi.nlm.nih.gov/20029553
Autor:
Jon Henrik, Laake, Jon Bragi, Bergmann, Fridtjov, Riddervold, Arvid, Bjørneklett, Pål, Aukrust, Stig S, Frøland
Publikováno v:
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 124(6)
Xigris (recombinant human activated protein C) has recently been introduced as a treatment for severe sepsis following a large multicentre trial (the PROWESS trial).Critical review of the original paper, follow-up studies and commentaries, and subgro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::040a33d1d9349c44996766fda5ee678a
https://pubmed.ncbi.nlm.nih.gov/15195189
https://pubmed.ncbi.nlm.nih.gov/15195189
Autor:
Erik Schrumpf, Jon Bragi Bergmann, Tom H. Karlsen, Kirsten Muri Boberg, O Bentdal, Kristian Bjøro, Pål-Dag Line, Anniken Bjørnstad Østensen, Bjarte Fosby, Jon Hausken, Stein Foss, T. Scholz, Fridtjov Riddervold, Håkon Haugaa, Truls Sanengen, Aksel Foss, P. F. Jørgensen, Svein Osnes
Publikováno v:
Tidsskrift for Den norske legeforening. 130:593-593
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b96b4786de5c70eaee937b7645108a5
https://doi.org/10.4045/tidsskr.10.0148
https://doi.org/10.4045/tidsskr.10.0148